Research group sessions
Plenary lectures
Main Symposia
Committee sessions
Special sessions
Sponsored sessions
Corporate symposia
| RS1 Research group on beta cell biology and islet transplantation & genetics joint session : Beta cell and genetics in diabetes |
15:00~17:00 / Thursday 6 October Convention Hall A, 4F Chairman:Ki-Ho Song, Sung-Hoon Kim |
Overview |
|---|---|---|
| This is the first joint research group session of KDA. Beta cell biology & islet transplantation research group and genetics of diabetes research group will join forces focusing on genetics of beta cell. Professor Anna L. Gloyn, recipient of 2022 ADA outstanding scientific achievement, will share her insights on beta cell dysfunction from genetics of type 2 diabetes. Professor Soo Heon Kwak will present recent work on how beta cell function declines as a function of increased genetic risk. Professor Josep Maria Mercader will introduce a useful resource on genetic variants that regulate islet specific gene expression. Professor Joonyub Lee will present on the detailed process of loss of beta cell identity in early diabetes. | ||
|
RS1-1Human genetics as a model for target validation: finding new therapies for diabetes | |
|
RS1-2Genetics of diabetes and beta-cell function in East Asians | |
|
RS1-3TIGER: the gene expression regulatory variation landscape of human pancreatic islets | |
|
RS1-4Characterizing the process of loss of β-cell identity by mouse model for early diabetes | |
| RS2 Research group on diabetic neuropathy session : Diabetic painful neuropathy: patient stratification by symptom and sensory profiling |
15:00~17:00 / Thursday 6 October Convention Hall C, 4F Chairman:Jihyun Lee, Dong-Hyeok Cho |
Overview |
|---|---|---|
| This session entitled with ‘Diabetic Peripheral Neuropathy—New ideas and Strategies for therapeutic targets’ is translational session and designed to provide a place for clinicians to understand the proper managements of diabetic peripheral neuropathy(DPN) in people with diabetes. Neuropathic pain is defined as pain as a result of a lesion or disease of the somatosensory nervous system. In a recent cluster analysis, it has been shown that patients with peripheral neuropathic pain can be grouped into sensory phenotypes. In this session, we had focus on patient stratification by symptom and sensory profiling, change of Nerve and brain in DPN and lipids: a new potential therapeutic target in DPN with 3 speakers and 3 panelist. This session will be provide the better understanding of management of DPN. | ||
|
RS2-1Diabetic neuropathy: what does the future hold? | |
|
RS2-2Nerve and brain in diabetic peripheral neuropathy | |
|
RS2-3Relationship between lipids and diabetic neuropathy: a new potential therapeutic target? | |
|
RS2-4Panel discussion | |
|
RS2-5Panel discussion | |
| RS3 Research group on diabetic nephropathy session : Diabetic kidney disease: from mechanisms to therapies |
15:00~17:00 / Thursday 6 October Emerald Hall A, 3F Chairman:Hunjoo Ha, Nan Hee Kim |
Overview |
|---|---|---|
| Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease. Recent studies have shown that SGLT2 inhibitors and finerenone could delay the progression of DKD. Besides, several novel mechanisms suggest therapeutic targets. In this session, four eminent researchers will discuss the role of recent promising drugs on DKD and new therapeutic targets for DKD with their data. Please join this session to share the latest knowledge. | ||
|
RS3-1Emerging targets of diabetic kidney disease | |
|
RS3-2Mechanistic insight toward understanding the therapeutic effect of finerenone in diabetic kidney disease | |
|
RS3-3Targeting nox in aging and diabetes | |
|
RS3-4Role of the lysosomal transcription factor TFEB in podocyte injury in diabetic kidney disease | |
| RS4 Research group on fatty liver disease session : NAFLD: from epidemiology to therapeutics |
15:00~17:00 / Thursday 6 October Diamond Hall, 3F Chairman:Cheol-Young Park, Byung-Wan Lee |
Overview |
|---|---|---|
| This session entitled with ‘NAFLD: from epidemiology to therapeutics’ is a clinical and basic research session and designed to focus on recent hot topics regarding epidemiology of MAFLD issues and mechanism/therapeutics of NASH. Prof. Sachiyo Yoshio from Japan will deliver the role of macrophages in NASH fibrosis and Prof. Chan Wah Kheong from Malaysia will share the recent consensus in MAFLD definition. Prof. Dae Won Jun will focus on risk factors of lean NAFLD and Prof. Yong-ho Lee will present the data of a novel GLP1/GLP2 receptor dual target agent for NASH treatment. | ||
|
RS4-1Macrophages as a source of fibrosis biomarkers for non-alcoholic fatty liver disease | |
|
RS4-2Recent issues in MAFLD | |
|
RS4-3Diabetes is the strongest risk factor of hepatic fibrosis in lean patients with non-alcoholic fatty liver disease | |
|
RS4-4GLP1/GLP2 receptor dual agonist to treat NASH: targeting the gut-liver axis and microbiome | |
